Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634351 | 1.00 | EPHX2 (0.41) | EPHX2CHEK2MAP4K4CYP2C9CYP2J2 | |
| SCHEMBL29324903 | 1.00 | EPHX2 (0.41) | EPHX2CHEK2MAP4K4CYP2C9CYP2J2 | |
| SCHEMBL31540092 | 0.89 | HRH1 (0.43) | EPHX2MAP4K4CYP2C9CYP2J2IKBKB | |
| SCHEMBL20400026 | 0.89 | HRH1 (0.43) | EPHX2MAP4K4CYP2C9CYP2J2IKBKB | |
| SCHEMBL26098186 | 0.82 | GRIN1 (0.43) | EPHX2CYP2C9CYP2J2IKBKBGRIN1 | |
| SCHEMBL77615 | 0.81 | PARP10 (0.48) | EPHX2IKBKBHRH1PARP10CYP19A1 | |
| SCHEMBL28179921 | 0.81 | CYP19A1 (0.44) | EPHX2IKBKBHRH1PARP10CYP19A1 | |
| SCHEMBL15574985 | 0.80 | MAP4K4 (0.39) | EPHX2MAP4K4CYP2C9CYP2J2IKBKB | |
| SCHEMBL14654942 | 0.80 | CYP19A1 (0.49) | EPHX2IKBKBHRH1GRIN1GRIN2B | |
| SCHEMBL15574983 | 0.80 | MAP4K4 (0.39) | EPHX2MAP4K4CYP2C9CYP2J2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102924445-A | PIM kinase inhibitor, preparation method thereof, and application thereof in pharmacy | SHANGHAI JIKAI MEDICAL TECHNOLOGY CO LTD | 2013-02-13 | — | — | CN | claimed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025081082-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024263586-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2014074668-A1 | MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-2556056-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| CN-102924445-A | PIM kinase inhibitor, preparation method thereof, and application thereof in pharmacy | SHANGHAI JIKAI MEDICAL TECHNOLOGY CO LTD | 2013-02-13 | — | — | CN | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012170702-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | EPHX2 2795/4885CHEK2 4830/4885MAP4K4 2363/4885 |
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | EPHX2 1439/4885CHEK2 753/4885MAP4K4 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.